SPOTLIGHT: Isis gains from big RNAi deal


Alnylam wasn't the only biotech company to score on Wall Street after the announcement of its rich RNAi deal with Roche. Isis Pharmaceuticals stands to gain $26.6 million along with milestones and royalties in the deal, and investors bid up its stock price by 17 percent. Isis licensed its RNAi tech to Alnylam in 2004. Report